Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Companyâs Response to the CRL for CARDAMYSTâą (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025
What are the broader implications for MLND's pipeline and future cash flow projections given the revised regulatory timeline?
How might this news affect the trading volume and liquidity of MLND shares in the short term?
Will the updated timeline impact analyst coverage or consensus estimates for MLND's 2025 financial performance?
27 days ago